Cantor Fitzgerald reiterated their buy rating on shares of Neos Therapeutics (NASDAQ:NEOS) in a report released on Friday. Cantor Fitzgerald currently has a $20.00 price target on the stock.

“. Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month PT of $20 for NEOS shares. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think continued success with the sales of its key drugs (Adzenys XR-ODT, Cotempla XR- ODT and Adzenys ER) as well as pipeline advancements (NT-0400 and NT-0501) will drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher.”,” the firm’s analyst commented.

Several other equities research analysts also recently weighed in on NEOS. ValuEngine raised Neos Therapeutics from a strong sell rating to a sell rating in a report on Thursday, July 12th. Zacks Investment Research downgraded Neos Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 25th. Finally, Wells Fargo & Co lowered their price target on Neos Therapeutics from $14.00 to $11.00 and set a buy rating for the company in a report on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $15.50.

NEOS stock traded up $0.01 during trading on Friday, reaching $2.59. 651,079 shares of the company traded hands, compared to its average volume of 621,268. Neos Therapeutics has a 12 month low of $2.27 and a 12 month high of $11.69. The company has a market cap of $83.38 million, a P/E ratio of -0.97 and a beta of 0.44.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Friday, November 9th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03). The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $14.80 million. Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%. On average, sell-side analysts predict that Neos Therapeutics will post -1.8 EPS for the current fiscal year.

In other Neos Therapeutics news, Director Alan L. Heller purchased 43,478 shares of the stock in a transaction on Thursday, November 8th. The stock was acquired at an average price of $2.30 per share, with a total value of $99,999.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.40% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Neos Therapeutics by 1.5% in the third quarter. BlackRock Inc. now owns 2,122,751 shares of the company’s stock worth $10,295,000 after purchasing an additional 31,469 shares during the last quarter. Nexthera Capital LP purchased a new position in shares of Neos Therapeutics in the second quarter worth about $2,369,000. Proxima Capital Management LLC raised its stake in shares of Neos Therapeutics by 34.1% in the second quarter. Proxima Capital Management LLC now owns 295,000 shares of the company’s stock worth $1,844,000 after purchasing an additional 75,000 shares during the last quarter. Northern Trust Corp raised its stake in shares of Neos Therapeutics by 10.7% in the second quarter. Northern Trust Corp now owns 294,678 shares of the company’s stock worth $1,842,000 after purchasing an additional 28,378 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in shares of Neos Therapeutics by 22.1% in the third quarter. Essex Investment Management Co. LLC now owns 285,716 shares of the company’s stock worth $1,386,000 after purchasing an additional 51,744 shares during the last quarter. Hedge funds and other institutional investors own 46.88% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Further Reading: Day Trading – Risk Worth the Reward?

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.